Rapid Micro Biosystems, INC 8-K filings

Rapid Micro Biosystems reported an 11% increase in second-quarter revenue to $8.1 million and a significant improvement in gross margin to 15%, while reaffirming full-year guidance.

Rapid Micro Biosystems stockholders elected a Class II director and ratified the appointment of its independent auditor at the 2026 Annual Meeting.

Rapid Micro Biosystems, Inc. announced the closing of an underwritten offering of common stock and warrants, raising approximately $9 million.

Rapid Micro Biosystems reported an 11% increase in first-quarter 2026 revenue to $8.0 million, driven by product and recurring revenue growth, though net loss expanded to $14.3 million.

Rapid Micro Biosystems announced Chief Operating Officer John Wilson's departure, with CEO Robert Spignesi taking on principal operating officer duties.

Rapid Micro Biosystems announced record fourth quarter and full year 2025 financial results, alongside significant multi-system orders from Amgen and Samsung Biologics, and provided 2026 guidance.

Rapid Micro Biosystems, Inc. announced preliminary unaudited record revenue for the fourth quarter and full year 2025, exceeding raised guidance.

Rapid Micro Biosystems announced strong third-quarter 2025 financial results, including record recurring revenue and a historic multi-system order, leading to raised full-year revenue and system placement guidance.

Rapid Micro Biosystems secured a new $45 million term loan facility and reported a 10% increase in second-quarter 2025 revenue, reaffirming full-year guidance.

Rapid Micro Biosystems, Inc. CEO Robert Spignesi announced a recent diagnosis of treatable Lymphoma, stating he expects to continue actively leading the company during his approximately four-month treatment period.

Rapid Micro Biosystems, Inc. reported the resignation of director Jeffrey Schwartz and the results of its annual stockholders' meeting, including the election of two Class I directors and the ratification of its independent auditor.

Rapid Micro Biosystems announces strong first quarter 2025 financial results, highlighted by a 28% increase in total revenue and a significant improvement in gross margin.

Rapid Micro Biosystems updates its corporate presentation, emphasizing growth strategy, collaborations, and a financial outlook targeting at least $32M in revenue for 2025.

Rapid Micro Biosystems (RPID) announces strong Q4 and full-year 2024 results, driven by revenue growth and improved gross margins, and unveils a global distribution agreement with MilliporeSigma.

Rapid Micro Biosystems has partnered with MilliporeSigma in a global distribution and collaboration agreement to expand the reach of its Growth Direct systems.

Rapid Micro Biosystems announced strong preliminary 2024 results, including a 25% revenue increase and a shift to positive gross margins in the latter half of the year.

Rapid Micro Biosystems reports record preliminary revenue for the fourth quarter and full year 2024, alongside a significant collaboration with Lonza.

Rapid Micro Biosystems has regained compliance with Nasdaq's minimum bid price requirement after its stock price closed above $1.00 for ten consecutive business days.

Rapid Micro Biosystems announced record third quarter revenue of $7.6 million, a 24% increase year-over-year, and achieved positive gross margins for the first time.

Rapid Micro Biosystems reported a 32% increase in second-quarter revenue and announced an operational efficiency program to achieve positive cash flow by 2027.

Rapid Micro Biosystems held its annual meeting, amended its charter to include officer exculpation, and elected three Class III directors.

Rapid Micro Biosystems announced an 11% increase in first-quarter revenue to $5.6 million and reaffirmed its full-year revenue guidance of at least $27 million.

Rapid Micro Biosystems announced a 45% revenue increase in Q4 2023 and provided 2024 revenue guidance of at least $27 million, signaling strong growth and improved financial performance.

Rapid Micro Biosystems has received a notification from Nasdaq that its stock price has fallen below the minimum bid price requirement, putting its listing at risk.